Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126141243 | 12614124 | 3 | F | 20160721 | 20160802 | 20160823 | EXP | CN-JNJFOC-20160800485 | JANSSEN | YANG H, CHEN Z, WU M, LEI T, YU H, GE M. REMARKABLE RESPONSE IN 2 CASES OF ADVANCED POORLY DIFFERENTIATED THYROID CARCINOMA WITH LIPOSOMAL DOXORUBICIN PLUS CISPLATIN. CANCER BIOLOGY AND THERAPY 2016;17/6:693-697. | 57.00 | YR | A | F | Y | 0.00000 | 20160823 | MD | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126141243 | 12614124 | 1 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Unknown | DAY 1 | N | 0 | 35 | MG/M**2 | LIPOSOME INJECTION | ||||||
| 126141243 | 12614124 | 2 | PS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Unknown | DAY 1 | N | 50718 | 35 | MG/M**2 | LIPOSOME INJECTION | ||||||
| 126141243 | 12614124 | 3 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Unknown | DAY 1 | Y | 0 | 35 | MG/M**2 | LIPOSOME INJECTION | ||||||
| 126141243 | 12614124 | 4 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Unknown | DAY 1 | Y | 0 | 35 | MG/M**2 | LIPOSOME INJECTION | ||||||
| 126141243 | 12614124 | 5 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | DAY 1 TO DAY 3 | Y | 0 | 75 | MG/M**2 | UNSPECIFIED | ||||||
| 126141243 | 12614124 | 6 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | DAY 1 TO DAY 3 | Y | 0 | 75 | MG/M**2 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126141243 | 12614124 | 1 | Metastases to lung |
| 126141243 | 12614124 | 2 | Poorly differentiated thyroid carcinoma |
| 126141243 | 12614124 | 3 | Metastases to lung |
| 126141243 | 12614124 | 4 | Poorly differentiated thyroid carcinoma |
| 126141243 | 12614124 | 5 | Metastases to lung |
| 126141243 | 12614124 | 6 | Poorly differentiated thyroid carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126141243 | 12614124 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126141243 | 12614124 | Bone marrow failure | |
| 126141243 | 12614124 | Off label use | |
| 126141243 | 12614124 | Palmar-plantar erythrodysaesthesia syndrome | |
| 126141243 | 12614124 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126141243 | 12614124 | 1 | 20131117 | 20140211 | 0 | |
| 126141243 | 12614124 | 2 | 20131117 | 20140211 | 0 | |
| 126141243 | 12614124 | 3 | 20131117 | 20140211 | 0 | |
| 126141243 | 12614124 | 4 | 20131117 | 20140211 | 0 | |
| 126141243 | 12614124 | 5 | 20131117 | 20140211 | 0 | |
| 126141243 | 12614124 | 6 | 20131117 | 20140211 | 0 |